Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant718 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 |
| PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER |
| recruiting |
| Phase 2 |
| 30 |
| Banner HealthOTHER |
| 1 |
| May 1, 2026 |
| clinicaltrials |
| NCT06385691 | Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.(MyDIET) | recruiting | Phase 2 | 60 | Centre Leon BerardOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07542262 | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers(NIVO402025) | enrolling by invitation | Phase 2 | 128 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04725994 | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 87 | Idience Co., Ltd.INDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT07537348 | Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer(LUCENT-GC-03) | recruiting | Phase 2 | 73 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537361 | Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer(LUCENT-GC-02) | recruiting | Phase 2 | 108 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03259867 | Combination of TATE and PD-1 Inhibitor in Liver Cancer(TATE-PD1) | recruiting | Phase 2 | 54 | Teclison Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04745988 | An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer | active not recruiting | Phase 2 | 43 | National Cancer Center Hospital EastOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05034887 | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 64 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07517107 | Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer | recruiting | Phase 2 | 600 | Fudan UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05184803 | A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | recruiting | Phase 2 | 63 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07515625 | Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07507526 | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer(DTP-HER2) | not yet recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507916 | Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 32 | Fudan UniversityOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT05515796 | Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | completed | Phase 2 | 189 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT00512304 | Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)(TRACE) | completed | Phase 2 | 63 | University Hospital, RouenOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07492615 | A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 276 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07486310 | Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial | not yet recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07277439 | Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma | recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06256328 | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | active not recruiting | Phase 2 | 226 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT07320586 | Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | recruiting | Phase 2 | 40 | Shandong Tumor HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT07391826 | Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07374250 | Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma(Huaxi) | not yet recruiting | Phase 2 | 154 | Sichuan UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2026source: clinicaltrials